The research, led by Associate Professor Jeffrey Wardell, director of York University’s Behavioural Alcohol and Cannabis Research Lab (BAC Lab), addresses an urgent public health concern emerging in the post-legalization era of cannabis in Canada. With cannabis use on the rise among young adults, understanding why these individuals often concurrently consume alcohol and cannabis—and how such behavior correlates with mental health—is increasingly essential for developing effective intervention strategies. Wardell emphasizes that while occasional combined use may seem innocuous, the data substantiate heightened risks associated with such patterns, especially among those grappling with adverse emotional states.

Underlying the study is a sophisticated longitudinal design employing intensive daily self-reports collected via mobile surveys administered in three 21-day bursts spaced six months apart. Participants documented their alcohol and cannabis intake and detailed any negative repercussions encountered. Complementing this, they reported on psychological symptomatology related to depression, anxiety, and stress alongside their motivations for combining substances. This multi-temporal approach enables a nuanced examination of the bidirectional relationships between internal states and co-use behaviors, a methodological advancement over cross-sectional analyses traditionally employed in substance use research.

Results compellingly demonstrate that young adults experiencing heightened internalizing symptoms are more prone to using alcohol and cannabis simultaneously, often with the explicit motive of intensifying psychoactive effects—“doubling up” to achieve a heightened state of intoxication. Wardell elaborates that this cyclical pattern appears driven primarily by attempts at emotional self-regulation, with participants indicating that combining substances momentarily alleviated negative feelings. However, this short-term relief paradoxically escalated the frequency of binge drinking episodes paired with cannabis use, leading to cascading adverse outcomes spanning physical health, psychological well-being, and socio-environmental domains.

Delving deeper into the neurodevelopmental context, the study situates these behavioral patterns within the prolonged maturation trajectory of the young adult brain, which continues refining executive functions and emotional regulation well into the mid-20s. Given that dependencies on substances such as alcohol and cannabis are disproportionately observed within this age group, the findings hold particular salience. Wardell notes that exposure to combined substances during this sensitive developmental window likely compounds the risk of maladaptive neural plasticity, exacerbating susceptibility to enduring substance use disorders and mental health challenges.

Beyond mechanistic insights, the study importantly underscores the long-term ramifications of the simultaneous use of alcohol and cannabis. While participants acknowledged the temporary mitigation of distress through substance use, Wardell cautions that these behaviors are linked to elevated incidences of negative life events, including academic, occupational, and interpersonal difficulties. Such outcomes reinforce the pressing need for early detection and intervention frameworks designed to address co-use behaviors, particularly when motivated by maladaptive coping strategies.

Highlighting the translational potential of these findings, Wardell advocates for a multi-pronged approach to prevention and treatment, centered on fostering healthier alternative coping mechanisms. Techniques such as mindfulness meditation, controlled breathing exercises, and physical activity can serve as effective adjuncts or substitutes for substance use in regulating distress. Peer support networks and professional counseling services further constitute vital resources. The study also draws attention to accessible online screening tools that can empower young adults to self-assess substance-related risks, especially those linked to reliance on psychoactive agents for emotional relief.

The study’s methodological rigor stems from its longitudinal survey approach, which enables the capture of temporal fluctuations in both affective symptoms and substance use motives. This design circumvents recall biases commonly encountered in retrospective surveys and illuminates dynamic within-person processes that inform intervention timing and targeting. The granular data reveal that the propensity to simultaneously consume alcohol and cannabis escalates notably during periods characterized by acute depressive or anxious states, emphasizing the episodic nature of risk.

In considering the broader epidemiological implications, Wardell situates the findings within the evolving landscape of cannabis legalization and shifting societal norms around substance use. The normalization of cannabis has potentiated its integration into casual and heavy alcohol consumption routines, raising complex questions about polysubstance interactions and public health messaging. The study’s emphasis on young adults is especially prescient, given that this cohort not only exhibits the highest rates of co-use but also stands at a critical juncture where preventive efforts can substantially alter life course trajectories.

A key contribution of the study lies in elucidating specific motivational pathways that connect internalizing symptoms to simultaneous substance use. Contrary to simplistic models which treat co-use as merely additive effects of alcohol and cannabis consumption, Wardell’s team delineates how psychological distress uniquely modulates usage patterns through motives framed around alleviating negative affect and enhancing intoxication. This distinction has profound implications for tailoring clinical assessments and interventions that attend to motivational underpinnings rather than solely behavioral manifestations.

Moreover, the research reveals an urgent necessity for integrating mental health assessments into substance use interventions for young adults. Traditional siloed approaches may overlook the intricacies of co-occurring internalizing disorders and polysubstance behaviors, thereby limiting their efficacy. By contrast, informed therapeutic paradigms that concurrently address mood disturbances and substance co-use could disrupt trajectories toward entrenched addiction and chronic psychological impairment.

Wardell’s findings also illuminate emerging challenges and opportunities within digital health, as the study leverages mobile technology to enable real-time data capture. This method not only enhances ecological validity but also opens avenues for just-in-time adaptive interventions (JITAI) that respond dynamically to fluctuations in psychological distress and substance use cues. Such innovations could revolutionize both research methodologies and clinical practices targeting young adult populations.

Ultimately, this landmark study from York University contributes compelling evidence that the psychological landscape of young adults profoundly shapes their substance use behaviors, especially in the context of simultaneous alcohol and cannabis consumption. As policymakers, clinicians, and educators grapple with the public health implications of shifting substance use paradigms, research such as this furnishes a critical foundation for nuanced, evidence-based responses—aimed at mitigating harms while respecting the developmental and psychosocial realities of emerging adulthood.

Subject of Research: People

Article Title: Internalizing symptoms are indirectly associated with simultaneous alcohol and cannabis use through specific motives for simultaneous use: A longitudinal study of young adults

News Publication Date: 9-Sep-2025

Web References:
https://onlinelibrary.wiley.com/doi/10.1111/acer.70147

References:
Wardell, J. et al., 2025. Internalizing symptoms are indirectly associated with simultaneous alcohol and cannabis use through specific motives for simultaneous use: A longitudinal study of young adults. Alcohol Clinical and Experimental Research. DOI: 10.1111/acer.70147

Keywords:
Cannabis, Alcohol abuse, Mental health

New York State law strictly prohibits the purchase of cannabis products from unlicensed vendors and forbids sales to individuals under the age of 21. Despite these prohibitions, the study reveals that the unregulated marketplace continues to thrive, offering products that evade adherence to vital safety disclosures. Licensed retailers, contrastingly, comply with rigorous standards mandating transparency concerning potency, expiration, dosing information, and health warnings intended to safeguard consumers. This study’s evidence underscores the urgency of legislative and enforcement measures to bridge the regulatory divide between licensed and unlicensed markets.

Ryan Sultán, assistant professor of clinical psychiatry at Columbia University Vagelos College of Physicians and Surgeons and a lead investigator, points to the critical risks posed by this gap in regulation: “Our research indicates a pervasive deficit in product safety compliance that jeopardizes consumer well-being. Coordinated efforts between state and federal agencies are imperative to enforce clear labeling standards and to curtail deceptive packaging tactics that undermine informed consumption.” His insights echo broader concerns about the intersection of public health and cannabis commercialization in rapidly evolving legal landscapes.

In the context of New York’s regulated cannabis market, licensed retailers are required to provide comprehensive labeling that details THC potency—a psychoactive compound directly influencing intoxication levels—and clearly state product quality, usage instructions including ‘use-by’ dates, and standardized health warnings. The purpose is to facilitate safe, responsible use and minimize potential adverse health effects linked to improper dosing or exposure to unverified substances. By contrast, the study reveals that products from unlicensed sources frequently omit these critical disclosures, creating an opaque consumer environment.

Moreover, licensees are legally barred from marketing cannabis products with medical claims or targeting minors. Yet, the researchers observed widespread dissemination of products featuring vibrant, playful designs, cartoon imagery, and child-appealing fonts, particularly among those sold in unregulated venues. The packaging aesthetics, often designed to attract younger demographics, raise serious ethical and regulatory concerns regarding youth exposure and initiation risks. This finding is troubling given the demonstrated susceptibility of adolescent brains to the neuropsychological impacts arising from early cannabis use.

The rapid expansion of legal cannabis markets has inadvertently catalyzed a parallel surge in unlicensed retailers, who operate with less oversight and accountability. These merchants frequently offer cannabis products that bypass quality assurance protocols, raising the specter of consumption-related hazards ranging from excessive THC dosage to contamination by harmful substances. The proliferation of unregulated cannabis necessitates vigilant surveillance and public education to mitigate the consequences of unverified product consumption.

The Columbia-led study employed a comparative analysis of 88 cannabis products procured from both licensed and unlicensed retailers within New York City. The stark contrasts documented illuminated a grim reality: only approximately 3% of unlicensed products manifested the full spectrum of six mandated New York State health warnings and safety features, whereas nearly 50% of licensed items conformed to these requirements. Such disparities underscore the systemic shortcomings of unlicensed channels in delivering safe, transparent cannabis products to consumers.

An additional layer of concern lies in the prevalent mislabeling observed among unlicensed products. These items frequently displayed official-looking symbols appropriated from other states’ regulatory systems—California’s universal cannabis symbol being an example—or else incorporated irrelevant warnings typical to edible cannabis products on non-edible items. This form of deceptive labeling not only confuses consumers but also undermines interstate regulatory harmonization and consumer trust.

Timothy Becker, the study’s lead author and current assistant professor of clinical psychiatry at Weill Cornell Medicine, accentuates these dangers: “The absence of clear, accurate labels significantly elevates the risk of unintended consumption effects. Consumers are often unaware of the true potency and potential hazards associated with these unregulated products, leading to documented cases of acute toxicity and longer-term health complications.” Becker’s perspective situates the labeling issue within a broader discourse on cannabis safety and consumer protection.

Another revealing dimension from the study is the packaging styles utilized by both licensed and unlicensed sellers. While nearly all sampled products employed bright, multicolored designs and playful fonts—elements that could inadvertently appeal to minors—about 25% of unlicensed products prominently featured cartoon characters or other graphic elements explicitly designed to attract children and teenagers. Licensed products avoided such imagery, highlighting adherence to stricter marketing guidelines in the regulated sector.

Sultán voices particular alarm over this trend, stating, “The prevalence of child-targeted packaging in the unlicensed market is a deeply concerning public health issue. At a time when cannabis consumption among adolescents is linked to cognitive and behavioral risks, it is vital that packaging does not serve as a gateway appeal to this vulnerable group.” These concerns amplify calls for tighter restrictions on cannabis marketing and packaging content nationwide.

The data and analyses presented in this research articulate an urgent policy challenge: balancing the benefits of cannabis legalization and commercialization with the imperative to protect public health, particularly among underage groups and inexperienced users. The revelations of regulatory laxity within unlicensed sectors call for enhanced enforcement mechanisms and potentially, technological innovations such as blockchain tracking or tamper-evident packaging to ensure comprehensive accountability.

Published in the American Journal of Preventive Medicine, the study titled “Labeling of cannabis products from licensed and unlicensed retailers in New York” not only elucidates the current regulatory landscape’s deficiencies but also serves as a clarion call for multi-level interventions. Supported by the National Institutes of Health, this research contributes vital evidence needed to guide policymakers, public health officials, and the cannabis industry toward safer, more transparent product distribution standards.

As cannabis legalization continues to evolve nationwide, the findings stress the importance of robust labeling requirements and packaging regulations that prioritize consumer safety and deny marketing avenues appealing to youth. Without such structured oversight, the expansion of unlicensed cannabis commerce threatens to undercut decades of regulatory progress, potentially exacerbating public health risks and eroding public confidence in cannabis as a legally controlled substance.

Subject of Research: Labeling and packaging compliance disparities between licensed and unlicensed cannabis retailers in New York State.
Article Title: Labeling of cannabis products from licensed and unlicensed retailers in New York
News Publication Date: Not specified
Web References: http://dx.doi.org/10.1016/j.amepre.2025.108000
References: Published in the American Journal of Preventive Medicine, authors Timothy D. Becker, Peter J. Menzi, Mark Olfson, Polina Mosharova, Frances R. Levin, and Ryan S. Sultán
Image Credits: Not specified
Keywords: Cannabis, Cannabis labeling, Cannabis packaging, Cannabis regulation, THC potency, Public health, Unlicensed cannabis retailers